Literature DB >> 9649200

Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy.

U Sundin1, S Nava, L Hammarström.   

Abstract

Patients with IgA deficiency often demonstrate circulating antibodies against IgA, which have been suggested to be associated with transfusion reactions. Sera from three patients with common variable immunodeficiency (CVID) and one with a selective IgA deficiency with anti-IgA antibodies receiving subcutaneous gammaglobulin replacement therapy were analysed for serum levels of IgG, IgA and anti-IgA before and during a treatment period of 4-7 years. Treatment with gammaglobulin preparations containing significant amounts of IgA (< 5 mg/ml) resulted in a decrease or disappearance of the anti-IgA antibodies. Analysis of serum fractions, however, revealed anti-IgA activity in the complex-containing fractions. In vitro experiments gave similar results with a shift of anti-IgA activity from the monomeric to the complex-containing fractions (that could not be detected in whole serum). When the patients were subsequently switched to treatment with a preparation containing less IgA (< 80 microg/ml) or made an interruption in the treatment schedule, the anti-IgA antibodies reappeared. Importantly, however, one of the patients lost his anti-IgA activity during a 3-month period on the preparation containing the higher IgA levels, and these antibodies did not reappear after switching to the low IgA-containing preparation. After 5 years on this preparation, anti-IgA can still not be detected, suggesting induction of unresponsiveness.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9649200      PMCID: PMC1904967          DOI: 10.1046/j.1365-2249.1998.00571.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Use of an IgA-depleted intravenous immunoglobulin in a patient with an anti-IgA antibody.

Authors:  C Cunningham-Rundles; S Wong; J Björkander; L A Hanson
Journal:  Clin Immunol Immunopathol       Date:  1986-02

2.  Anti-IgA antibody associated reactions to intravenous gammaglobulin in a patient who tolerated intramuscular gammaglobulin.

Authors:  S J Frankel; S H Polmar; F C Grumet; H J Wedner
Journal:  Ann Allergy       Date:  1986-05

3.  Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA.

Authors:  A W Burks; H A Sampson; R H Buckley
Journal:  N Engl J Med       Date:  1986-02-27       Impact factor: 91.245

4.  Cross-linking of B lymphocyte Fc gamma receptors and membrane immunoglobulin inhibits anti-immunoglobulin-induced blastogenesis.

Authors:  N E Phillips; D C Parker
Journal:  J Immunol       Date:  1984-02       Impact factor: 5.422

5.  Anti-IgA in selective IgA deficiency. In vitro effects and Ig subclass pattern of human anti-IgA.

Authors:  L Hammarström; M A Persson; C I Smith
Journal:  Scand J Immunol       Date:  1983-12       Impact factor: 3.487

6.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

7.  Treatment of acute idiopathic thrombocytopenia of childhood with intravenous infusions of gammaglobulin.

Authors:  J B Bussel; A Goldman; P Imbach; I Schulman; M W Hilgartner
Journal:  J Pediatr       Date:  1985-06       Impact factor: 4.406

8.  Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies.

Authors:  Y Sultan; F Rossi; M D Kazatchkine
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

9.  Activation of the alternative pathway of complement by human serum IgA.

Authors:  P S Hiemstra; A Gorter; M E Stuurman; L A Van Es; M R Daha
Journal:  Eur J Immunol       Date:  1987-03       Impact factor: 5.532

10.  Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies.

Authors:  J Björkander; L Hammarström; C I Smith; R H Buckley; C Cunningham-Rundles; L A Hanson
Journal:  J Clin Immunol       Date:  1987-01       Impact factor: 8.317

View more
  17 in total

1.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.

Authors:  Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz
Journal:  J Allergy Clin Immunol Pract       Date:  2015-11-07

2.  Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration.

Authors:  Isabella Quinti; Annarosa Soresina; Carlo Agostini; Giuseppe Spadaro; Andrea Matucci; Ifigeneia Sfika; Helene Martini; Federica Borghese; Andrea Guerra; Vultaggio Alessandra; Marcella Visentini; Alessandro Plebani; Massimo Fiorilli
Journal:  J Clin Immunol       Date:  2008-05       Impact factor: 8.317

Review 3.  Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.

Authors:  Hassan Abolhassani; Mohammad Salehi Sadaghiani; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2012-06-23       Impact factor: 8.317

4.  IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy.

Authors:  R de Albuquerque Campos; M N Sato; A J da Silva Duarte
Journal:  J Clin Immunol       Date:  2000-01       Impact factor: 8.317

Review 5.  Use of intravenous immunoglobulin in pediatric practice.

Authors:  Bülent Zülfikar; Başak Koç
Journal:  Turk Pediatri Ars       Date:  2014-12-01

Review 6.  Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease.

Authors:  S Jolles; J S Orange; A Gardulf; M R Stein; R Shapiro; M Borte; M Berger
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

7.  Long-Term Treatment and Transfusion of Normal Blood Components Following Tolerance Induction in Patients with Anti-IgA Anaphylactic Reactions.

Authors:  Abdulgabar Salama; Romina Kardashi; Olga Arbach
Journal:  Transfus Med Hemother       Date:  2014-09-15       Impact factor: 3.747

8.  Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.

Authors:  Suzanne Skoda-Smith; Troy R Torgerson; Hans D Ochs
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

9.  Subcutaneous immunoglobulin-g replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens.

Authors:  Akhilesh Chouksey; Kimberly Duff; Nancy Wasserbauer; Melvin Berger
Journal:  Allergy Asthma Clin Immunol       Date:  2005-09-15       Impact factor: 3.406

10.  Immune tolerance induction in patients with IgA anaphylactoid reactions following long-term intravenous IgG treatment.

Authors:  N Ahrens; C Höflich; S Bombard; H Lochs; H Kiesewetter; A Salama
Journal:  Clin Exp Immunol       Date:  2008-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.